VIA
IMNM icon

Virtus Investment Advisers’s Immunome IMNM Stock Holding History

Virtus Investment Advisers’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$377K Buy
17,802
+3,870
+28% +$82.8K 0.09% 315
2026
Q1 		$305K Buy
13,932
+339
+2% +$7.54K 0.08% 275
2025
Q4 		$292K Buy
13,593
+1,970
+17% +$34.6K 0.08% 259
2025
Q3 		$136K Buy
11,623
+2,018
+21% +$20.1K 0.04% 392
2025
Q2 		$89.3K Sell
9,605
-2,956
-24% -$24.2K 0.03% 382
2025
Q1 		$84.5K Buy
+12,561
New +$121K 0.02% 445

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Virtus Investment Advisers's IMNM Position: Q2 2026 in Review

Virtus Investment Advisers increased its Immunome (IMNM) stake by 28% in Q2 2026, buying an estimated $82.8K and bringing the position to 17,802 shares worth $377K. The position accounts for 0.09% of the portfolio, ranked #315.

Virtus Investment Advisers first reported a position in IMNM in Q1 2025 and has held it in 6 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Virtus Investment Advisers held 17,802 shares of Immunome worth $377K as of Q2 2026.
  • Virtus Investment Advisers bought 3,870 Immunome shares in Q2 2026, an estimated $82.8K.
  • Immunome made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #315 holding.
  • Virtus Investment Advisers first reported a position in Immunome in Q1 2025 and has held it in 6 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.